免疫检查点抑制剂致肺部不良反应的诊治进展

doi:10.16150/j.1671-2870.2021.04.003

摘要/Abstract

中图分类号:

R730.51

王晓斐, 张秋蕊. 免疫检查点抑制剂致肺部不良反应的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 343-348.

图/表 2

参考文献 29

[1]	Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015,26(12):2375-2391. doi: 10.1093/annonc/mdv383 pmid: 26371282
[2]	Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. doi: 10.1093/annonc/mdv623 pmid: 26715621
[3]	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015,373(3):288-290. doi: 10.1056/NEJMc1505197 URL
[4]	Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors[J]. Int J Cancer, 2019,145(3):639-648. doi: 10.1002/ijc.32132 pmid: 30653255
[5]	Ma K, Lu Y, Jiang S, et al. The Relative Risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis[J]. Front Pharmacol, 2018,9:1430. doi: 10.3389/fphar.2018.01430 URL
[6]	Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453 pmid: 27540850
[7]	Jiang Y, Zhang N, Pang H, et al. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Ther Clin Risk Manag, 2019,15:293-302. doi: 10.2147/TCRM.S191022 URL
[8]	Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systema-tic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923 URL
[9]	Granier C, de Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer[J]. ESMO Open, 2017,2(2):e000213. doi: 10.1136/esmoopen-2017-000213 URL
[10]	Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells?[J]. Clin Cancer Res, 2015,21(22):5047-5056. doi: 10.1158/1078-0432.CCR-15-0685 pmid: 26567364
[11]	Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018,8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367 URL
[12]	Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J]. J Exp Med, 2009,206(13):3015-3029. doi: 10.1084/jem.20090847 URL
[13]	Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012,12(4):252-264. doi: 10.1038/nrc3239 pmid: 22437870
[14]	Soto F, Zhong L, Shannon VR, et al. Incidence and risk factors for pneumonitis associated with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer: A single center experience[J/OL]. J Clin Oncol, 2020,38(15_suppl):e15089-e15089.
[15]	Wu J, Hong D, Zhang X, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis[J]. Sci Rep, 2017,7:44173. doi: 10.1038/srep44173 URL
[16]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. doi: 10.1200/JCO.2016.68.2005 URL
[17]	Huang Y, Fan H, Li N, et al. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: systematic review and network meta-analysis[J]. Cancer Med, 2019,8(5):2664-2674. doi: 10.1002/cam4.2104 URL
[18]	Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J]. Lung Cancer, 2020,150:76-82. doi: 10.1016/j.lungcan.2020.08.015 URL
[19]	Hakozaki T, Richard C, Okuma Y, et al. Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy[J]. J Clin Oncol, 2020,38(15_suppl):3095-3095. doi: 10.1200/JCO.19.02103 URL
[20]	Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients[J]. Eur J Cancer, 2019,109:21-27. doi: S0959-8049(18)31453-9 pmid: 30682533
[21]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. doi: 10.1200/JCO.2016.68.2005 URL
[22]	Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2019,20(4):e470-e479.
[23]	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247. doi: 10.1016/j.ejca.2008.10.026 pmid: 19097774
[24]	Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420. doi: 10.1158/1078-0432.CCR-09-1624 pmid: 19934295
[25]	Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016,22(24):6051-6060. pmid: 27535979
[26]	Ferguson EC, Berkowitz EA. Lung CT: Part 2, The interstitial pneumonias--clinical, histologic, and CT manifestations[J]. Am J Roentgenol, 2012,199(4):W464-W476.
[27]	Gkiozos I, Kopitopoulou A, Kalkanis A, et al. Sarcoidosis-like reactions induced by checkpoint Inhibitors[J]. J Thorac Oncol, 2018,13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031 URL
[28]	中华医学会呼吸学会分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019,42(11):820-825.
[29]	Pollack MH, Betof A, Dearden H, et al. Safety of resu-ming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma[J]. Ann Oncol, 2018,29(1):250-255. doi: 10.1093/annonc/mdx642 pmid: 29045547

分级	ICIs	糖皮质激素	随访
G1	推迟	排除感染后开始口服甲泼尼松龙1~2 mg/（kg·d）	达到稳定后,恢复肿瘤免疫治疗
G2	暂停	排除感染后开始口服甲泼尼松龙1~2 mg/（kg·d）	糖皮质激素在至少8周内逐渐减量至停药;糖皮质激素减量至≤10 mg/d恢复肿瘤免疫治疗
G3、G4	可考虑永久停药	静脉注射（甲基）泼尼松龙2~4 mg/（kg·d）	糖皮质激素在至少8周内逐渐减量至停药;如48 h后未改善或恶化,加用英利昔单抗5 mg/kg、麦考酚酸酯（并发肝损伤）、环磷酰胺

免疫检查点抑制剂致肺部不良反应的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许晓倩, 卿恺, 张苏江. 造血干细胞移植后非感染性肺部并发症的诊治进展[J]. 诊断学理论与实践, 2021, 20(06): 515-521.
[2]	顾卫琼. 免疫检查点抑制剂致甲状腺损伤的诊治进展[J]. 诊断学理论与实践, 2021, 20(04): 338-342.
[3]	游碧君, 王金辉, 庄鸿源. 儿童输血反应发生率及输血反应原因分析和改进措施探讨[J]. 诊断学理论与实践, 2021, 20(04): 396-398.
[4]	周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[5]	刘海霞, 瞿介明. 肺部微生态及其与肺癌关系的研究进展[J]. 诊断学理论与实践, 2019, 18(05): 496-502.
[6]	康健捷, 杨红军, 邓兵梅, 邵腾飞. 利福平致药源性流感样综合征一例临床分析[J]. 诊断学理论与实践, 2018, 17(04): 460-461.
[7]	金燕萍, 朱敏华, 江铭. 临床输血不良反应情况分析及预防措施探讨[J]. 诊断学理论与实践, 2016, 15(05): 503-506.
[8]	陈克敏, 黄蔚, 王晴柔,. 肺部结节的诊断和处置[J]. 诊断学理论与实践, 2013, 12(02): 155-156.
[9]	山洁慧, 胡炯,. 造血干细胞移植后肺部并发症的诊断和治疗[J]. 诊断学理论与实践, 2012, 11(04): 422-427.
[10]	施裕新, 张志勇, 王月波,. 肺部真菌病感染的放射学诊断[J]. 诊断学理论与实践, 2010, 9(02): 116-119.
[11]	顾志冬, 郑子佳, 毛客自, 樊绮诗,. 肿瘤标志物在鉴别伴有胸水的良恶性肺部疾病中的应用价值[J]. 诊断学理论与实践, 2007, 6(04): 309-314.
[12]	陈俊,徐鹤定,王祖承. 精神药物在综合性医院中的使用[J]. 诊断学理论与实践, 2005, 4(04): 355-360.
[13]	郭强,顾越英,陈晓翔,赵江峰,叶霜,杨程德,黄绍光. 血清KL-6对狼疮性间质性肺炎与肺部感染的鉴别意义[J]. 诊断学理论与实践, 2004, 3(04): 26-28.
[14]	马大庆. 多层螺旋CT多平面重建对肺内病变的诊断价值[J]. 诊断学理论与实践, 2004, 3(03): 10-11+15.
[15]	戎霞君,郝翠兰. 系统性红斑狼疮合并肺结核一例分析[J]. 诊断学理论与实践, 2003, 2(01): 83-84.